Aligos Therapeutics (NASDAQ:ALGS) Announces Quarterly Earnings Results, Misses Expectations By $0.92 EPS

Aligos Therapeutics (NASDAQ:ALGS) announced its quarterly earnings results on Wednesday. The company reported ($3.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92), Zacks reports. The company had revenue of $1.27 million during the quarter, compared to analysts’ expectations of $1.00 million. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same period last year, the firm earned ($10.25) earnings per share.

Aligos Therapeutics Stock Up 2.7 %

NASDAQ:ALGS traded up $0.27 during midday trading on Friday, reaching $10.19. The stock had a trading volume of 108,249 shares, compared to its average volume of 39,795. The stock has a market cap of $32.61 million, a P/E ratio of -0.50 and a beta of 2.11. The firm has a fifty day simple moving average of $9.81 and a two-hundred day simple moving average of $12.63. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $30.00.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a research report on Thursday.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).